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Acute coronary syndromes (ACS) such as unsta-
ble angina and acute myocardial infarction is 
caused by the rupture of the atherosclerotic 
plaque and subsequent thrombosis [1]. Under 
these conditions, antiplatelet drugs, angiotensin 
converting enzyme inhibitor, β-blocker and HMG
-CoA reductase inhibitors (statins) were shown 
to decrease the secondary cardiovascular event 
significantly [2-6]. Particularly statins strongly 
decrease low-density lipoprotein-cholesterol 
(LDL-C) and stabilize vulnerable plaque [6, 7]. 
Indeed, early use of the statin in ACS decreased 
the plaque volume determined by intravascular 
ultrasound 6 months after treatment [8]. In not 
only ACS but also in stable coronary syndrome, 
we previously reported that statins reduced 
coronary plaque volume in Japanese patients 
[9]. However, few data exist regarding how early 
statins can change plaque composition and 
volume in clinical settings.  
 
Recently, coronary plaque composition can be 
evaluated with not only invasive methods such 
as IVUS and optical coherence tomography but 
also with non-invasive one such as coronary CT 
angiography (CCTA) [10, 11]. Previous studies 
demonstrated CCTA exhibited good agreement 
with intravascular ultrasound in terms of evalu-
ating plaque composition [12, 13]. In addition, 
repeated examination in short term could be 
done by CCTA except problems regarding use of 
contrast agent and radiation exposure. The aim 
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Abstract: Although intensive lipid lowering by statins can enhance plaque stability, few data exist regarding how early 
statins change plaque composition and morphology in clinical setting. Therefore, to examine early changes in plaque 
composition and morphology by intensive lipid lowering with statins, we evaluate coronary plaques from acute coro-
nary syndrome (ACS) before and 3 weeks after lipid lowering by coronary CT angiography. We enrolled 110 patients 
with suspected ACS and underwent coronary CT. We defined plaque as unstable when CT number of plaque< 50HU 
and remodeling index (lesion diameter/reference diameter) >1.10. Rosuvastatin (5 mg/day) or atorvastatin (20 mg/
day) were introduced to reduce low density lipoprotein cholesterol (LDL-C). Then, CT was again performed by the 
same condition 3 weeks after lipid lowering therapy. Total 10 patients (8 men, mean age 72.0 years), in whom in-
formed consent regarding serial CT examination was obtained, were analyzed. Among them, 4 patients who denied to 
have intensive lipid lowering were served as controls. In remaining 6 patients, LDL-C reduced from 129.5±26.9 mg/dl 
to 68.5±11.1 mg/dl after statin treatment. Under these conditions, CT number of the targeted plaque significantly 
increased from 16.0±15.9 to 50.8±35.0 HU (p<0.05) and remodeling index decreased from 1.22±0.11 to 
1.11±0.06 (p<0.05), although these values substantially unchanged in controls. These results demonstrate that 
MDCT-determined plaque composition as well as volume could be changed within 3 weeks after intensive lipid lower-
ing. This may explain acute effects of statins in treatment of acute coronary syndrome.  
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of this study was to evaluate changes in plaque 
composition and morphology in early phase 
such as 3 weeks after intensive lipid lowering by 
CCTA.  
 
Materials and methods 
 
Participants and study design 
 
We enrolled 110 patients who were suspected 
of ACS and were examined by 64-slice CCTA 
from Janurary 2009 to March 2011. Base line 
characteristics included age, sex, LDL-C, high-
density lipoprotein cholesterol (HDL-C) and LDL-
C/HDL-C. When unstable plaque defined as de-
scribed below was detected by CCTA, we admin-
istered statins such as rosuvastatin of 5mg/day 
or atorvastatin of 20 mg/day and re-evaluated 





The 64-slice CCTA scanning (Light Speed VCT, 
GE, USA) was performed with retrospective ECG 
gating. β-blocker such as propranolol of 20mg 
to 60mg was injected before scanning to de-
crease heart rate to 60 beats/min in average.  
Nitroglycerin of 0.3 mg was used for coronary 
artery dilatation. All image acquisitions were 
performed during a single breath-hold after in-
spiration. Scanning was performed with condi-
tion of effective tube current from 220 mA to 
780 mA, effective tube voltage of 120 kV, 
0.625 mm slice acquisition, and gantry rotation 
time of 350 ms. We performed contrast-
enhanced scanning using 0.8 ml/kg contrast 
medium (Iopamidol  370, Bayer Healthcare, 





CCTA images were analyzed using commercially 
available soft ware (Advantage Workstation Vol-
ume Share 4.3). For plaque detection, both 
cross-sectional view, stretched view and curved 
multiplanar reformation images were used for 
analysis. Under these conditions, we chose the 
coronary segment with ?2 mm in diameter. The 
coronary arterial remodeling was defined as a 
ratio of vessel diameter at the plaque site in 
comparison with that in the reference segment 
set proximal to the lesion in a normal-appearing 
vessel segment (reference segment). The re-
modeling index (lesion diameter/reference di-
ameter) in cross-sectional view on CCTA was 
calculated and reported as positive remodeling 
when the diameter at the plaque site was at 
least 10% larger than the reference segment 
[13, 14]. We defined plaque attenuation as 
minimum CT density of the average of each 3 
slices, and defined plaques as unstable when 
CT value ?50HU [10]. Three weeks after statin 
therapy, same evaluation before statin therapy 
was repeatedly performed for follow up patients. 
Data analyses  
 
The quantitative variables are presented as 
mean ± standard deviation and categorical data 
are shown as proportions. Mean values were 
compared using the paired t test. P-value  




Among enrolled 110 patients, informed consent 
regarding the intensive statin therapy and re-
peated CCTA examination in 3 week was ob-
tained in 6 patients (5 men, mean age 72.0 
years, Table 1). The remaining 4 agreed with 
only repeated CT examination without intensive 
lipid lowering. There were 2 patients with diabe-
tes mellitus, one patient with hypertension, 4 
patients with hyperlipidemia and 2 patients with 
habit of smoking. There were 3 patients pre-
scribing rosuvastatin and 3 patients prescribing 
Table1. Patients’ characteristics before statin treatment 
  Age Sex LDL(mg/dl) HDL(mg/dl) CT attenuation(HU) Remodeling index 
1 75 male 102 66 21.26 1.13 
2 71 male 111 25 11.25 1.12 
3 63 male 146 40 -8.43 1.36 
4 76 male 113 39 17.00 1.36 
5 71 male 174 43 14.25 1.20 
6 79 female 131 57 40.83 1.13 
  72.0±5.6   129.5±26.9 45±14.5 16．0±15.9 1.22±0.11 
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atorvastatin. Six of all had coronary plaques 
which were characterized by positive remodel-




A 63 year-old Japanese male had acute myocar-
dial infarction and performed percutaneous 
coronary intervention for left anterior descend-
ing coronary artery. We performed CCTA after 
PCI and atorvastatin of 20 mg was adminis-
trated. Three weeks after statin therapy, LDL-C 
decreased from 146mg/dl to 71mg/dl, HDL-C 
increased from 33mg/dl to 40mg/dl, yielding 
reduced LDL-C/HDL-C from 3.86 to 2.15. Under 
these conditions, cross sectional view on MDCT 
showed the increased signal of target lesion 
from -8 HU to 39 HU with decreased remodeling 
index from 1.36 to 1.19 (Figure 1). 
Lipid profiling and plaque analysis 
 
In all 6 patients, LDL-C decreased significantly 
from 129.5 ± 26.9 mg/dl to 68.5 ± 11.1 mg/dl, 
or by 47% (p<0.05) (Figure 2). HDL-C substan-
tially unchanged from 39.2 ± 8.8 mg/dl to 45.0 
± 14.5 mg/dl. Thus, LDL-C/HDL-C decreased 
significantly from 3.14 ± 1.10 to 1.80 ± 0.39, or 
by 42.6%.  
 
CT number of the plaque increased significantly 
from 16.0 ± 15.9 HU to 50.8 ± 35.0 HU 
(p<0.05) and remodeling index decreased from 
1.22±0.11 to 1.11±0.06 (p<0.05) (Figure 2). In 
controls, there were no significant changes in 
these values during 3 weeks. Although it is in-
teresting to correlate changes in LDL-C levels 
and those in plaque composition and/or mor-
phology, there were no correlations between 





The present study demonstrates that CCTA-
determined plaque composition and morphol-
ogy can be changed in only 3 weeks after start-
ing intensive lipid lowering with statins. This 
may explain early effects of statin-induced in-
tensive lipid lowering on prevention of cardio-
vascular events early after the occurrence of 
ACS.  
 
Previous clinical trials showed that clinical bene-
fit of statin therapy was observed within one 
month in patients with ACS [15-17]. However, 
few data exist demonstrating changes in plaque 
composition and morphology in early phase af-
ter statin therapy except findings observed by 
carotid ultrasound and virtual histology ultra-
sound [15, 16]. The present 
study demonstrates that in-
tensive LDL-C reduction by 
47% in average can cause 
changes in CCTA-determined 
plaque composition and mor-
phology within only 3 weeks. 
Figure 1. Coronary CT images of curved view (A), 
stretched view (B), and cross sectional view (C) be-
fore and after intensive lipid lowering therapy. Arrows 
indicate the target lesion and circles indicate the 
region of interests. 
Figure 2. Changes in low density 
lipoprotein-cholesterol (LDL-C) (A), 
in CT attenuation; (B) and in re-
modeling index (C) before and after 
intensive lipid lowering therapy 
Open circles indicate mean values 
of each data.  
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In the experimental study, high cholesterol-
induced atherosclerotic endothelial dysfunction 
could be diminished in 2 weeks after statin 
treatment [18]. In the present study, there were 
no correlations between changes in LDL-C levels 
and those in plaque morphology and composi-
tions probably due to small number of patients, 
although previous invasive studies demon-
strated correlation between them [8, 17]. This 
may be explained by the period of repeated CT 
examination is too short to obtain the mature 
changes in plaque morphology and composi-
tion. 
 
In the evaluation of plaques, we used CCTA in-
stead of intravascular ultrasound or optical co-
herence tomography both of which were already 
established as methods for plaque evaluation. It 
is reasonable to consider that CCTA was appar-
ently less invasive than intravascular imaging 
techniques. In addition, recent studies showed 
the plaque exhibiting positive remodeling and 
low-attenuation on CCTA was consistent with 
vulnerable plaque on intravascular ultrasound 
[12, 19, 20]. Soeda et al evaluated coronary 
plaque with CCTA before and after statin ther-
apy for 24 weeks [21], and found that CT-
determined plaque composition could be 
changed 24 weeks or 6 months after statin 
therapy.    
 
Clinical implications and limitation 
 
The most important clinical implication of the 
present study is how rapid plaque composition 
and/or morphology could change after intensive 
lipid lowering. Although experimental studies 
indicated that atherosclerotic plaque composi-
tion changes quickly after discontinuation of 
high cholesterol diet or stating statin therapy, 
this should take longer time in clinical setting. 
Indeed, previous imaging studies were per-
formed by evaluating plaque at least 3 months 
for intervals. Particularly for ACS patients, we 
should give statins to establish intensive lipid 
lowering for 3 weeks, and plaque stabilization 
can be obtained.  
 
There remain, however, several limitations in 
the present study, First, the study size was 
small mainly due to difficulty to obtain the in-
formed consent for the present study in which 
repeated CT examinations with radiation expo-
sure after intensive lipid lowering therapy were 
performed. However, it is evident that CCTA-
determined plaque composition and morphol-
ogy could be changed rapidly after intensive 
lipid lowering in ACS patients, although a large-
scale randomized control study should be per-
formed to confirm our result. Second, although 
spatial resolution of 64-slice CCTA has been 
improved compared to previous CT system, par-
tial volume effect and CT attenuation of coro-
nary lumen influence the CT attenuation of tar-
get plaque. We expect more advancement in CT 
technology to improve spatial resolution, which 





In the present study, we demonstrate that CCTA-
determined plaque composition as well as mor-
phology could be immediately changed after 
starting intensive lipid lowering in ACS. We sug-
gest that in ACS coronary narrowing as well as 
plaque composition and morphology should be 
evaluated by CCTA for possible indication of 
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